Trial Profile
Effectiveness and safety of Apatinib combined SOX regimen for conversion therapy of unresectable advanced gastric cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 May 2018
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Liver metastases
- Focus Adverse reactions; Therapeutic Use
- 17 May 2018 New trial record